Skip to main content
Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.005
+0.205 (11.39%)
Jun 6, 2025, 3:08 PM - Market open

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023
Period Ending
 Dec '24 Dec '23
Autologous Tumor Infiltrating Lymphocyte Cell Therapies
164.07M
Log In
Autologous Tumor Infiltrating Lymphocyte Cell Therapies Growth
13698.99%
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023
Period Ending
 Dec '24 Dec '23
United States
161.04M
Log In
United States Growth
13444.41%
Log In
Rest of World
3.03M
Log In